Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
26.27
-0.11 (-0.42%)
Sep 24, 2026, 4:00 PM EDT - Market closed
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $129.86M in the quarter ending June 30, 2026, with 59.33% growth. This brings the company's revenue in the last twelve months to $463.98M, up 76.11% year-over-year. In the year 2025, Arcutis Biotherapeutics had annual revenue of $376.07M with 91.34% growth.
Revenue (ttm)
$463.98M
Revenue Growth
+76.11%
P/S Ratio
7.12
Revenue / Employee
$1,310,681
Employees
354
Market Cap
3.30B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 376.07M | 179.53M | 91.34% |
| Dec 31, 2024 | 196.54M | 136.94M | 229.74% |
| Dec 31, 2023 | 59.61M | 55.92M | 1,517.09% |
| Dec 31, 2022 | 3.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Telix Pharmaceuticals | 890.79M |
| Tarsus Pharmaceuticals | 606.33M |
| IDEAYA Biosciences | 234.13M |
| Arcus Biosciences | 117.00M |
| uniQure | 18.67M |
| Xenon Pharmaceuticals | 7.50M |
| Denali Therapeutics | 3.60M |
ARQT News
- 7 days ago - Arcutis Biotherapeutics falls -5.1% - TheFly
- 8 days ago - Arcutis Biotherapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 8 days ago - Arcutis Biotherapeutics rises 7.7% - TheFly
- 20 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire
- 23 days ago - Arcutis Biotherapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Oruka Therapeutics appoints Todd Edwards as chief commercial officer - TheFly
- 7 weeks ago - Arcutis Biotherapeutics price target raised to $38 from $34 at Morgan Stanley - TheFly